An important possible implication of the ability of sAPPα to facilitate FPN1 activity is that increased gene dosage of APP (e.g., due to duplication mutations or in Down syndrome) could potentially cause excess sAPPα secretion from neurons that might act to stabilize FPN1 on the plasma membranes of proximal cells. This evidence concerns the gene SLC40A1 and Down syndrome.